PubMed

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.PMID: 17430582 [PubMed - indexed for MEDLINE]Related articlesFree article

Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.

Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, et al.

Clin Cancer Res. 1995 Feb;1(2):189-98.PMID: 9815973 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.PMID: 18380893 [PubMed - indexed for MEDLINE]Related articlesFree article

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ.

J Clin Oncol. 1998 Feb;16(2):470-9.PMID: 9469330 [PubMed - indexed for MEDLINE]Related articles

Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN.

Breast J. 2002 Jan-Feb;8(1):2-9.PMID: 11856154 [PubMed - indexed for MEDLINE]Related articles

Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.

Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, Maucione A, Kenda R, Zucali R, Veronesi U.

J Natl Cancer Inst. 1997 May 7;89(9):639-45.PMID: 9150188 [PubMed - indexed for MEDLINE]Related articlesFree article

Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.

Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, Ghosh N, Trivedi TI.

Ann Surg Oncol. 2000 May;7(4):305-11.PMID: 10819372 [PubMed - indexed for MEDLINE]Related articles

Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.

Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S.

Jpn J Clin Oncol. 1997 Dec;27(6):371-7.PMID: 9437997 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa C, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G.

Ann Oncol. 2006 Oct;17(10):1504-11. Epub 2006 Sep 12.PMID: 16968874 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.PMID: 18505968 [PubMed - indexed for MEDLINE]Related articlesFree article

Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.

Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T.

Int J Oncol. 1998 May;12(5):1117-25.PMID: 9538138 [PubMed - indexed for MEDLINE]Related articles

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N.

J Clin Oncol. 2005 Jun 1;23(16):3686-96. Epub 2005 May 16.PMID: 15897552 [PubMed - indexed for MEDLINE]Related articles

Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.

Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.

Mod Pathol. 2002 Aug;15(8):853-61.PMID: 12181271 [PubMed - indexed for MEDLINE]Related articlesFree article

Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?

Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S.

J Surg Res. 2001 Aug;99(2):161-8.PMID: 11469882 [PubMed - indexed for MEDLINE]Related articles

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.

Clin Cancer Res. 2000 Jul;6(7):2751-8.PMID: 10914720 [PubMed - indexed for MEDLINE]Related articlesFree article

Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.

Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.

Jpn J Clin Oncol. 2005 Sep;35(9):514-9.PMID: 16199422 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI.

Ann Surg. 2001 May;233(5):630-8.PMID: 11323501 [PubMed - indexed for MEDLINE]Related articlesFree article

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N.

J Natl Cancer Inst Monogr. 2001;(30):62-6.PMID: 11773294 [PubMed - indexed for MEDLINE]Related articles

Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.

van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ.

Br J Cancer. 1996 Jul;74(1):78-85.PMID: 8679463 [PubMed - indexed for MEDLINE]Related articlesFree article

The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.

Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J.

Cancer. 2000 Feb 15;88(4):804-13.PMID: 10679650 [PubMed - indexed for MEDLINE]Related articlesFree article